Seeking Alpha

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...
Nasdaq

Tenaya Therapeutics Initiates Dosing in Cohort 2 of TN-201 Trial for Hypertrophic Cardiomyopathy and Provides 2025 Clinical Development Update

Tenaya Therapeutics updates on TN-201 and TN-401 gene therapies' clinical trials for cardiomyopathies, with data anticipated in 2025. Tenaya Therapeutics, a clinical-stage biotechnology company ...
Nasdaq

Tenaya Therapeutics Publishes Positive Preclinical Data for TN-201 Gene Therapy Targeting MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics reports positive preclinical data for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, published in Nature Communications. Tenaya Therapeutics, Inc. has ...
WREG

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 ...
Seeking Alpha

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially ...
Yahoo Finance

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...
Yahoo Finance

Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function

Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...
Mena FN

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function And Survival In MYBPC3 Cardiomyopathy Models

(MENAFN- GlobeNewsWire - Nasdaq) Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya's Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients ...